An abnormally low body temperature is too low.

An abnormally low body temperature is too low, acts on the brain, so that the victim is not well able to think clearly or move. This makes hypothermia particularly dangerous because a person does not know it can happen and is not in a position to do anything about it.

Keep the person warm while waiting for help to arrive. Do not apply direct heat, massage the person or alcoholic drinks, because a person could go into cardiac arrest, when the body is not properly warmed up.

How can I help someone, the symptoms of hypothermia? Get the person to a warm room or shelter. Remove wet clothing . Keep the person dry and wrapped in a warm blanket, at all times.e head and neck. Warm the center of the body of the first chest, head and abdomen, with an electric blanket, if available, or the use of skin-to-skin contact under loose, dry layers of blankets, clothing, towels, or sheets.Forward looking statements poster has at GenVec Web site the placard the poster, click on Investor Relations then click Webcasts and Data. .. The poster presentation entitled a phase I dose – escalation study of Ad GV. Figure 11D with concurrent radiotherapy and chemotherapy for patients with relapsed head and neck cancers , reports that 9 of 10 evaluable patients in the studies generated objective response rate to treatment. Of these patients, 4 attained complete clinical response RECIST tests Invite. Mark Thornton, GenVec ‘s Senior Vice President of of Product Development and, said: Prognosis for patients with recurrent the head and neck cancer arm is Early evidence of activity by TNFerade as well as radiochemotherapy in a setting encouraging in on which treatment of and supports the further to the TNFerade in this indication.

GenVec major drug candidate TNFerade, is currently in a pivotal clinical studies in locally advanced pancreatic carcinoma and additional clinical trials additional clinical studies to other types of tumors. GenVec utilizes its proprietary adenovector technology vaccine of diseases such as HIV, malaria, foot. And mouth disease, respiratory syncytial virus and flu developing additional information about GenVec is within society in society variety of filings with the Securities and Exchange Commission filings disposal.

Of these patients,ts from TNFerade Head Neck Cancer Study presenting at the ASCO.

Encouraging dates GenVec ‘ s stage I clinical trial to the TNFerade patients with head and neck tumors have been presented by lead investigator Everett Vokes, University of Chicago, to a poster session at the annual meeting the American Society of Clinical Oncology in Chicago..